Technical and biological constraints on ctDNA-based genoty**
Circulating tumor DNA (ctDNA) enables real-time genomic profiling of cancer without the
need for tissue biopsy. ctDNA-based technology is seeing rapid uptake in clinical practice …
need for tissue biopsy. ctDNA-based technology is seeing rapid uptake in clinical practice …
SmMIP-tools: a computational toolset for processing and analysis of single-molecule molecular inversion probes-derived data
Motivation Single-molecule molecular inversion probes (smMIPs) provide an exceptionally
cost-effective and modular approach for routine or large-cohort next-generation sequencing …
cost-effective and modular approach for routine or large-cohort next-generation sequencing …
Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA
The primary objective of the FDA-led Sequencing and Quality Control Phase 2 (SEQC2)
project is to develop standard analysis protocols and quality control metrics for use in DNA …
project is to develop standard analysis protocols and quality control metrics for use in DNA …
Elucidation of clinical implications Arising from circadian rhythm and insights into the tumor immune landscape in breast cancer
C Sun, H Zhang, Y Li, Y Yu, J Liu, R Liu, C Sun - Heliyon, 2024 - cell.com
Background Circadian rhythm is an internal timing system generated by circadian-related
genes (CRGs). Disruption in this rhythm has been associated with a heightened risk of …
genes (CRGs). Disruption in this rhythm has been associated with a heightened risk of …
Pan-cancer analyses reveal IGSF10 as an immunological and prognostic biomarker
Y Zhou, M Gao, Y **g, X Wang - Frontiers in Genetics, 2023 - frontiersin.org
Background: IGSF10 is a member of the immunoglobulin superfamily. Over the previous
decade, growing proof has validated definitive correlations between individuals of the …
decade, growing proof has validated definitive correlations between individuals of the …
BayVarC: an ultra-sensitive ctDNA variant caller using Bayesian approach
D Che, C Yan, J Zha, Z Niu, Q Yang, X Cheng, M Han… - bioRxiv, 2024 - biorxiv.org
In liquid biopsy, it is critical to detect variants of allele frequencies as low as 0.1% or even
lower, especially when used to monitor secondary resistant mutations and minimal residual …
lower, especially when used to monitor secondary resistant mutations and minimal residual …
The Molecular Determinants of Response to Immune Checkpoint Therapy in Solid Tumors
SYC Yang - 2022 - search.proquest.com
Immune checkpoint therapy (ICT) has demonstrated lasting clinical benefit unparalleled by
other cancer treatments in a small percentage of patients. Thus, optimizing patient selection …
other cancer treatments in a small percentage of patients. Thus, optimizing patient selection …
MinerVa: A high performance bioinformatic algorithm for the detection of minimal residual disease in solid tumors
P Yang, Y Zhang, L **a, J Mei, R Fan… - Sheng wu yi xue …, 2023 - europepmc.org
如何提高循环肿瘤 DNA (ctDNA) 信号的获取能力以及判定低频信号的真实性是肿瘤微小残留
病灶 (MRD) 检测的难点问题. 本研究开发了多变异联合置信概率分析的 MRD 生物信息学算法 …
病灶 (MRD) 检测的难点问题. 本研究开发了多变异联合置信概率分析的 MRD 生物信息学算法 …
[PDF][PDF] Minimal Disease Tracking by Next Generation Sequencing in AML
BA Anderson - 2023 - scholarship.miami.edu
Minimal Disease Tracking by Next Generation Sequencing in AML Page 1 Please do not
remove this page Minimal Disease Tracking by Next Generation Sequencing in AML …
remove this page Minimal Disease Tracking by Next Generation Sequencing in AML …
Multimodal Profiling of Cell-Free DNA for Detection and Characterization of Circulating Tumour DNA in Low Tumour Burden Settings
JM Burgener - 2022 - search.proquest.com
Circulating tumour DNA (ctDNA) is comprised of cell-free DNA (cfDNA) fragments released
into bodily fluids. ctDNA can enable personalized treatment strategies in oncology by …
into bodily fluids. ctDNA can enable personalized treatment strategies in oncology by …